Meeting
2014 Breast Cancer Symposium
A phase 1 study of dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple-negative breast cancer.
Authors
Zahi Mitri
The University of Texas MD Anderson Cancer Center, Houtston, TX
Zahi Mitri , Kansu Karakas , Nuhad K. Ibrahim , Ricardo H. Alvarez , James L. Murray , Brian Briones , Holly Simmons , Khandan Keyomarsi , Stacy L. Moulder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Risk Assessment, Prevention, Early Detection, Screening, and Systemic Therapy
Track
Systemic Therapy,Risk Assessment, Prevention, Early Detection, and Screening
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT01624441
Citation
J Clin Oncol 32, 2014 (suppl 26; abstr 163)
DOI
10.1200/jco.2014.32.26_suppl.163
Abstract #
163
Poster Bd #
E10
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Radioparp: A phase I of olaparib with radiation therapy (RT) in patients with inflammatory, locoregionally advanced or metastatic triple-negative breast cancer (TNBC) or patient with operated TNBC with residual disease—Preliminary results.
First Author: Youlia M. Kirova
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I results of the phase I/II study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer.
First Author: Saranya Chumsri
Poster
2013 ASCO Annual Meeting
A phase I study of neoadjuvant chemotherapy (NCT) with the gamma secretase (GS) inhibitor RO4929097 in combination with paclitaxel (P) and carboplatin (C) in women with triple-negative breast cancer (TNBC).
First Author: Ewa Mrozek
Poster
2012 ASCO Annual Meeting
Phase I trial of pegylated liposomal doxorubicin and lapatinib in the treatment of metastatic breast cancer (MBC): Final results.
First Author: Mary E. Cianfrocca